Dramatic results seen in phase III front-line multiple myeloma trials of bortezomib-based therapy

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2008年 / 22卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [41] Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma
    Li, Yang
    Yin, Ping
    Liu, Yang
    Hao, Chuanxi
    Chen, Lei
    Sun, Chao
    Wang, Sicong
    Hong, Nan
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [42] The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
    Robak, Pawel
    Drozdz, Izabela
    Jarych, Dariusz
    Mikulski, Damian
    Weglowska, Edyta
    Siemieniuk-Rys, Monika
    Misiewicz, Malgorzata
    Stawiski, Konrad
    Fendler, Wojciech
    Szemraj, Janusz
    Smolewski, Piotr
    Robak, Tadeusz
    CANCERS, 2020, 12 (09) : 1 - 18
  • [43] Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 389 - 394
  • [44] Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib
    Alagappan, Arti
    Shah, Rupin A.
    Thomas, Sheeba K.
    Weber, Donna M.
    Wang, Michael
    Alexanian, Raymond
    Orlowski, Robert Z.
    Shah, Jatin J.
    BLOOD, 2013, 122 (21)
  • [45] The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy
    Kwon, Jihyun
    Lee, Yong-Pyo
    Park, Hee Sue
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S101 - S101
  • [46] A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma
    Jagannath, S
    Brian, D
    Wolf, JL
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Mazumder, A
    Crowley, J
    Schenkein, D
    BLOOD, 2004, 104 (11) : 98A - 99A
  • [47] Phase III trials in ovarian cancer: The evolving landscape of front line therapy
    Naumann, R. Wendel
    Coleman, Robert L.
    Brown, Jubilee
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (02) : 436 - 444
  • [48] Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma
    Sopena, Maria
    Clavero, Estela Martin
    Villa, Paula
    Martinez-Lopez, Joaquin
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (03) : 147 - 154
  • [49] Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma
    Zhou, Xin
    Wang, Jing
    Xia, Jun
    Cheng, Feng
    Mao, Jingjue
    Zhu, Jianwei
    Guo, Hongfeng
    CANCER BIOMARKERS, 2018, 22 (01) : 43 - 48
  • [50] REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB-BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?
    Demirsoy, Esra Terzi
    Geduk, Ayfer
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2022, 25 (01): : 58 - 67
12345